Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
35 hedge funds and large institutions have $70.4M invested in Sinovac Biotech, Ltd in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 6 closing their positions.
148% more call options, than puts
Call options by funds: $697K | Put options by funds: $281K
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
49% more capital invested
Capital invested by funds: $47.2M → $70.4M (+$23.2M)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 33 → 35 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.4M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.06M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$806K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$515K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$438K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
-$5.52M |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$1.41M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$169K |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$104K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$96K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $21.5K | – | – | – |
|
27
Group One Trading
Chicago,
Illinois
| $9K | -$16.5K | -3,450 | -69% |
|
28
Bank of America
Charlotte,
North Carolina
| $8K | -$19.6K | -4,096 | -74% |
|
29
Creative Planning
Overland Park,
Kansas
| $6K | -$16.7K | -3,500 | -78% |
|
|
MFS
30
MSI Financial Services
Springfield,
Massachusetts
| $6K | – | – | – |
|
31
Wells Fargo
San Francisco,
California
| $4K | – | – | – |
|
|
AA
32
Apriem Advisors
Irvine,
California
| $2K | – | – | – |
|
33
Nomura Holdings
Tokyo,
Japan
| $2K | +$1.91K | +400 | New |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| $1K | -$96K | -20,083 | -99% |
|
|
ARTA
35
A.R.T. Advisors
New York
| – | -$169K | -43,175 | Closed |
|
|
RCM
36
Rotella Capital Management
Bellevue,
Washington
| – | -$104K | -26,429 | Closed |
|
|
U
37
UBS
Zurich,
Switzerland
| – | -$12.7K | -2,664 | Closed |
|
38
Barclays
London,
United Kingdom
| – | -$4K | -980 | Closed |
|
39
Ameriprise
Minneapolis,
Minnesota
| – | -$1K | -200 | Closed |
|
40
AllianceBernstein
Nashville,
Tennessee
| – | +$234 | +49 | New |
|
SVA Hedge Fund Activity: Q3 2013 in Review
35 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2013, worth a combined $70.4M — up 49% from $47.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SVA positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $2.4M. The largest seller was Davis Selected Advisers, cutting an estimated $5.52M.
- 35 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2013, up from 33 in Q2 2013.
- Funds reported $70.4M of Sinovac Biotech, Ltd stock for Q3 2013, up 49% quarter-over-quarter.
- 8 funds opened new Sinovac Biotech, Ltd positions in Q3 2013 and 6 closed out, a net change of +2 holders.
- The largest Sinovac Biotech, Ltd buyer in Q3 2013 was Renaissance Technologies, an estimated $2.4M added.
- The largest Sinovac Biotech, Ltd seller in Q3 2013 was Davis Selected Advisers, an estimated $5.52M sold.
Based on aggregated 13F filings for Q3 2013.